PDF(Pubmed)
Abstract：
OBJECTIVE: What is the impact of co-designed, evidence-based information regarding the anti-Mullerian hormone (AMH) test on women\'s interest in having the test?
CONCLUSIONS: Women who viewed the evidence-based information about the AMH test had lower interest in having an AMH test than women who viewed information produced by an online company selling the test direct-to-consumers.
BACKGROUND: Online information about AMH testing often has unfounded claims about its ability to predict fertility and conception, and evidence suggests that women seek out and are recommended the AMH test as a measure of their fertility potential.
METHODS: An online randomized trial was conducted from November to December 2022. Women were randomized (double-blind, equal allocation) to view one of two types of information: co-designed, evidence-based information about the AMH test (intervention), or existing information about the AMH test from a website which markets the test direct-to-consumers (control). A total of 967 women were included in the final analysis.
METHODS: Participants were women recruited through an online panel, who were aged 25-40 years, living in Australia or The Netherlands, had never given birth, were not currently pregnant but would like to have a child now or in the future, and had never had an AMH test. The primary outcome was interest in having an AMH test (seven-point scale; 1 = definitely NOT interested to 7 = definitely interested). Secondary outcomes included attitudes, knowledge, and psychosocial and behavioural outcomes relating to AMH testing.
RESULTS: Women who viewed the evidence-based information about the AMH test had lower interest in having an AMH test (MD = 1.05, 95% CI = 0.83-1.30), less positive attitudes towards (MD = 1.29, 95% CI = 4.57-5.70), and higher knowledge about the test than women who viewed the control information (MD = 0.75, 95% CI = 0.71-0.82).
CONCLUSIONS: The sample was more highly educated than the broader Australian and Dutch populations and some measures (e.g. influence on family planning) were hypothetical in nature.
CONCLUSIONS: Women have higher knowledge of and lower interest in having the AMH test when given evidence-based information about the test and its limitations. Despite previous studies suggesting women are enthusiastic about AMH testing to learn about their fertility potential, we demonstrate that this enthusiasm does not hold when they are informed about the test\'s limitations.
BACKGROUND: This project was supported by an NHMRC Emerging Leader Research Fellowship (2009419) and the Australian Health Research Alliance\'s Women\'s Health Research, Translation and Impact Network EMCR award. B.W.M. reports consultancy for ObsEva and Merck and travel support from Merck. D.L. is the Medical Director of, and holds stock in, City Fertility NSW and reports consultancy for Organon and honoraria from Ferring, Besins, and Merck. K.H. reports consultancy and travel support from Merck and Organon. K.M. is a director of Health Literacy Solutions that owns a licence of the Sydney Health Literacy Lab Health Literacy Editor. No other relevant disclosures exist.
BACKGROUND: ACTRN12622001136796.
UNASSIGNED: 17 August 2022.
UNASSIGNED: 21 November 2022.
CONCLUSIONS: Women who viewed the evidence-based information about the AMH test had lower interest in having an AMH test than women who viewed information produced by an online company selling the test direct-to-consumers.
BACKGROUND: Online information about AMH testing often has unfounded claims about its ability to predict fertility and conception, and evidence suggests that women seek out and are recommended the AMH test as a measure of their fertility potential.
METHODS: An online randomized trial was conducted from November to December 2022. Women were randomized (double-blind, equal allocation) to view one of two types of information: co-designed, evidence-based information about the AMH test (intervention), or existing information about the AMH test from a website which markets the test direct-to-consumers (control). A total of 967 women were included in the final analysis.
METHODS: Participants were women recruited through an online panel, who were aged 25-40 years, living in Australia or The Netherlands, had never given birth, were not currently pregnant but would like to have a child now or in the future, and had never had an AMH test. The primary outcome was interest in having an AMH test (seven-point scale; 1 = definitely NOT interested to 7 = definitely interested). Secondary outcomes included attitudes, knowledge, and psychosocial and behavioural outcomes relating to AMH testing.
RESULTS: Women who viewed the evidence-based information about the AMH test had lower interest in having an AMH test (MD = 1.05, 95% CI = 0.83-1.30), less positive attitudes towards (MD = 1.29, 95% CI = 4.57-5.70), and higher knowledge about the test than women who viewed the control information (MD = 0.75, 95% CI = 0.71-0.82).
CONCLUSIONS: The sample was more highly educated than the broader Australian and Dutch populations and some measures (e.g. influence on family planning) were hypothetical in nature.
CONCLUSIONS: Women have higher knowledge of and lower interest in having the AMH test when given evidence-based information about the test and its limitations. Despite previous studies suggesting women are enthusiastic about AMH testing to learn about their fertility potential, we demonstrate that this enthusiasm does not hold when they are informed about the test\'s limitations.
BACKGROUND: This project was supported by an NHMRC Emerging Leader Research Fellowship (2009419) and the Australian Health Research Alliance\'s Women\'s Health Research, Translation and Impact Network EMCR award. B.W.M. reports consultancy for ObsEva and Merck and travel support from Merck. D.L. is the Medical Director of, and holds stock in, City Fertility NSW and reports consultancy for Organon and honoraria from Ferring, Besins, and Merck. K.H. reports consultancy and travel support from Merck and Organon. K.M. is a director of Health Literacy Solutions that owns a licence of the Sydney Health Literacy Lab Health Literacy Editor. No other relevant disclosures exist.
BACKGROUND: ACTRN12622001136796.
UNASSIGNED: 17 August 2022.
UNASSIGNED: 21 November 2022.
摘要：
目标：共同设计的影响是什么，关于抗苗勒管激素(AMH)检测的循证信息对女性是否有兴趣进行检测？
结论：查看AMH检测循证信息的女性对AMH检测的兴趣低于查看由在线公司直接向消费者销售检测信息的女性。
背景：有关AMH测试的在线信息通常对其预测生育力和受孕的能力没有根据，有证据表明，女性寻求并建议使用AMH测试作为衡量其生育能力的指标。
方法：2022年11月至12月进行了一项在线随机试验。妇女被随机分配（双盲，均等分配)查看两种类型的信息之一：共同设计，关于AMH检验(干预)的循证信息，或有关AMH测试的现有信息，来自直接向消费者销售测试的网站（对照）。共有967名妇女被纳入最终分析。
方法：参与者是通过在线小组招募的女性，年龄在25-40岁之间，生活在澳大利亚或荷兰，从未生育过，目前没有怀孕，但现在或将来想要一个孩子，从未进行过AMH测试。主要结果是对AMH测试的兴趣（7点量表；1=绝对不感兴趣7=绝对感兴趣）。次要结果包括态度，知识,以及与AMH测试相关的社会心理和行为结果。
结果：查看AMH检验循证信息的女性对AMH检验的兴趣较低（MD=1.05，95％CI=0.83-1.30），不太积极的态度(MD=1.29，95%CI=4.57-5.70)，与查看对照信息的女性相比，对测试的知识更高（MD=0.75，95％CI=0.71-0.82）。
结论：与更广泛的澳大利亚和荷兰人口相比，该样本受教育程度更高，并且某些措施（例如对计划生育的影响）本质上是假设的。
结论：当提供有关测试及其局限性的循证信息时，女性对AMH测试的了解更高，兴趣更低。尽管以前的研究表明女性对AMH测试充满热情，以了解她们的生育潜力，我们证明，当他们被告知测试的局限性时，这种热情并不成立。
背景：该项目得到了NHMRC新兴领导者研究奖学金（2009419）和澳大利亚健康研究联盟妇女健康研究的支持。翻译和影响网络EMCR奖。B.W.M.报告了ObsEva和默克公司的咨询以及默克公司的旅行支持。D.L.是医学主任,并持有股票，新南威尔士州城市生育率和Ferring的Organon和酬金咨询报告，贝辛斯,和默克。K.H.报告了默克和Organon的咨询和旅行支持。K.M.是健康素养解决方案的主管，拥有悉尼健康素养实验室健康素养编辑的许可证。不存在其他相关披露。
背景：ACTRN12622001136796。
■2022年8月17日。
■2022年11月21日。
结论：查看AMH检测循证信息的女性对AMH检测的兴趣低于查看由在线公司直接向消费者销售检测信息的女性。
背景：有关AMH测试的在线信息通常对其预测生育力和受孕的能力没有根据，有证据表明，女性寻求并建议使用AMH测试作为衡量其生育能力的指标。
方法：2022年11月至12月进行了一项在线随机试验。妇女被随机分配（双盲，均等分配)查看两种类型的信息之一：共同设计，关于AMH检验(干预)的循证信息，或有关AMH测试的现有信息，来自直接向消费者销售测试的网站（对照）。共有967名妇女被纳入最终分析。
方法：参与者是通过在线小组招募的女性，年龄在25-40岁之间，生活在澳大利亚或荷兰，从未生育过，目前没有怀孕，但现在或将来想要一个孩子，从未进行过AMH测试。主要结果是对AMH测试的兴趣（7点量表；1=绝对不感兴趣7=绝对感兴趣）。次要结果包括态度，知识,以及与AMH测试相关的社会心理和行为结果。
结果：查看AMH检验循证信息的女性对AMH检验的兴趣较低（MD=1.05，95％CI=0.83-1.30），不太积极的态度(MD=1.29，95%CI=4.57-5.70)，与查看对照信息的女性相比，对测试的知识更高（MD=0.75，95％CI=0.71-0.82）。
结论：与更广泛的澳大利亚和荷兰人口相比，该样本受教育程度更高，并且某些措施（例如对计划生育的影响）本质上是假设的。
结论：当提供有关测试及其局限性的循证信息时，女性对AMH测试的了解更高，兴趣更低。尽管以前的研究表明女性对AMH测试充满热情，以了解她们的生育潜力，我们证明，当他们被告知测试的局限性时，这种热情并不成立。
背景：该项目得到了NHMRC新兴领导者研究奖学金（2009419）和澳大利亚健康研究联盟妇女健康研究的支持。翻译和影响网络EMCR奖。B.W.M.报告了ObsEva和默克公司的咨询以及默克公司的旅行支持。D.L.是医学主任,并持有股票，新南威尔士州城市生育率和Ferring的Organon和酬金咨询报告，贝辛斯,和默克。K.H.报告了默克和Organon的咨询和旅行支持。K.M.是健康素养解决方案的主管，拥有悉尼健康素养实验室健康素养编辑的许可证。不存在其他相关披露。
背景：ACTRN12622001136796。
■2022年8月17日。
■2022年11月21日。
